Patel Milan H, Blachman-Braun Ruben, Loebach Lauren, Millan Braden, Saini Jaskirat, Gurram Sandeep, Linehan W Marston, Ball Mark W
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Urol Oncol. 2025 Sep;43(9):525.e1-525.e8. doi: 10.1016/j.urolonc.2025.05.003. Epub 2025 May 27.
To present our experience with re-operative retroperitoneal partial nephrectomy (Re-RetroPN), evaluate its feasibility and safety, and compare perioperative outcomes, including renal function metrics, pathology, and complication rates, between patients that underwent Re-RetroPN and those that underwent re-operative transperitoneal robotic partial nephrectomy (Re-TransPN).
A retrospective cohort study was conducted identifying patients who underwent re-operative robotic partial nephrectomy (PN) at our institution from January 2008 to December 2024. Demographic, clinical, perioperative, and pathological data were recorded and analyzed.
A total of 186 patients who underwent robotic re-operative PN were analyzed (173 Re-TransPN vs. 13 Re-RetroPN), and 1 patient was converted from Re-RetroPN to Re-TransPN. Overall, 17 (9.1%) had a solitary kidney, 138 (74.2%) underwent their second ipsilateral partial nephrectomy, and 48 (25.8%) had their third. A total of 894 tumors were removed (825 with Re-TransPN, 69 with Re-RetroPN), with a median of 3 (2-6) tumors per procedure. Perioperative metrics, including estimated blood loss, operative time, and percentage of cases performed without hilar clamping were similar between groups. Positive surgical margins were observed in 7 (4.0%) patients in the Re-TransPN group, with no positive margins reported in the Re-RetroPN group. Renal function parameters at 3 months and complication rates were comparable between groups, with 1 (7.7%) patient in the Re-RetroPN group experiencing a Clavien-Dindo grade ≥3 complications.
Re-RetroPN is a feasible and safe option for carefully selected patients, with comparable outcomes to Re-TransPN. It provides advantages in certain scenarios, such as improved access to posteriorly located tumors and avoidance of the peritoneal cavity.
介绍我们开展再次手术腹膜后部分肾切除术(Re-RetroPN)的经验,评估其可行性和安全性,并比较接受Re-RetroPN患者与接受再次手术经腹机器人辅助部分肾切除术(Re-TransPN)患者的围手术期结局,包括肾功能指标、病理情况及并发症发生率。
进行一项回顾性队列研究,纳入2008年1月至2024年12月在我院接受再次手术机器人辅助部分肾切除术(PN)的患者。记录并分析人口统计学、临床、围手术期及病理数据。
共分析了186例接受机器人再次手术PN的患者(173例Re-TransPN vs. 13例Re-RetroPN),1例患者由Re-RetroPN转为Re-TransPN。总体而言,17例(9.1%)为孤立肾,138例(74.2%)接受同侧第二次部分肾切除术,48例(25.8%)接受第三次手术。共切除894个肿瘤(Re-TransPN组825个,Re-RetroPN组69个),每次手术切除肿瘤的中位数为3个(2 - 6个)。两组间围手术期指标,包括估计失血量、手术时间及未行肾门阻断手术的病例百分比相似。Re-TransPN组7例(4.0%)患者出现手术切缘阳性,Re-RetroPN组未报告切缘阳性病例。两组间3个月时的肾功能参数及并发症发生率相当,Re-RetroPN组1例(7.7%)患者出现Clavien-Dindo≥3级并发症。
对于精心挑选的患者,Re-RetroPN是一种可行且安全的选择,其结局与Re-TransPN相当。在某些情况下,它具有优势,如更易于处理位于后方的肿瘤及避免进入腹腔。